Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Amid political chatter about vaccines and the government entities that oversee them, it’s understandable to wonder where all this leaves the 2025-26 flu vaccine.

MRNA vaccines are "the most phenomenal medical breakthrough of the 21st century." And the excitement around them means a few grant cancellations—worth about $23 million per program, or less than 3% of ...

Covid-era coercion and misinformation bred public distrust, but the vaccines did save countless lives.